More than 500 million people worldwide are persistently infected with the hepatitis B virus
(HBV) and/or hepatitis C virus (HCV) and are at risk of developing chronic liver disease …

Since the discovery of the hepatitis C virus over 15 years ago, scientists have raced to
develop diagnostics, study the virus and find new therapies. Yet virtually every attempt to …

Hepatitis C virus (HCV) is a leading cause of cirrhosis and liver cancer worldwide. A better
understanding of the viral life cycle, including the mechanisms of entry into host cells, is …

The differentiation capacity of human embryonic stem cells (hESCs) holds great promise for
therapeutic applications. We report a novel three‐stage method to efficiently direct the …

Chronic liver disease caused by infection with hepatitis C virus (HCV) is an important global
health problem that currently affects 170 million people. A major impediment in HCV …

The tetraspanin web represents a new concept of molecular interactions in the immune
system. Whereas most surface immune-modulating molecules involve receptor–ligand …

Background & Aims: Broadly reactive neutralizing antibodies (nAbs) and multispecific T-cell
responses are generated during chronic hepatitis C virus (HCV) infection and yet fail to clear …

The lack of an efficient system to produce hepatitis C virus (HCV) particles has impeded the
analysis of the HCV life cycle. Recently, we along with others demonstrated that transfection …

Hepatitis C virus (HCV) is a major human pathogen associated with life-threatening liver
disease. Entry into hepatocytes requires CD81 and a putative second receptor. In this study …

The hepatitis C virus (HCV) is a remarkably successful pathogen, establishing persistent
infection in more than two-thirds of those who contract it. Its success is related to its abilities …